Highlights

  • Alcidion (ASX:ALC) will release its FY26 full-year results and host an investor webcast on 19 August 2026.
  • The University Hospitals Sussex agreement is worth about A$35 million over seven years, extendable to approximately A$49 million over ten years.
  • Half-year Revenue reached A$25.5 million, up 44 per cent YoY, while Recurring Revenue was A$19.3 million.
  • The Kyra Acquisition added 33 customers, including 31 new customers, for A$1.5 million net.

For a company that spent years teaching the market patience, Alcidion Group is moving faster. On 19 August the health-informatics software developer will release its FY26 accounts, and the result arrives after the busiest twelve months in the company's history. A landmark National Health Service contract, a bolt-on acquisition from Telstra Health, record quarterly Cash Flow and reconfirmed guidance have combined to reset expectations. The question now facing investors is not whether FY26 was a notable year — the June-quarter numbers already provided much of that picture — but whether the audited result and management's commentary can convert operational progress into a durable improvement in market expectations.

Latest Development

Alcidion confirmed on 12 August that it will release its FY26 full-year results and host an investor webcast on 19 August 2026, framing the event as the capstone to a year it has repeatedly described as record-breaking. The headline catalyst is University Hospitals Sussex, signed in May 2026: a seven-year agreement worth roughly A$35 million, extendable to about A$49 million across ten years, under which Sussex becomes the largest NHS trust to deploy a full electronic patient record built on the Miya Precision platform. Crucially, the deal carried an upfront Capital licence payment of A$10.6 million, banked in the June quarter, with a further A$8.5 million of revenue expected to be recognised. Alongside it, Alcidion closed the acquisition of Telstra Health's Kyra patient-flow products on 29 June for A$1.5 million net, adding 33 customers, 31 of them new.

What the Numbers Show

The interim scorecard is what gives the result its edge. Half-year revenue reached A$25.5 million, up 44 per cent year-on-year, with recurring revenue of A$19.3 million accounting for 76 per cent of the total — a predictable base of software income. Underlying EBITDA rose to A$4.2 million from A$541,000 a year earlier, and the company reported a net profit of A$1.33 million. The June quarter then delivered record Operating Cash Flow of A$7.7 million on cash receipts of A$24.6 million, lifting full-year operating cash flow to A$6.8 million, up 19 per cent. New contract value struck across FY26 totalled roughly A$78.5 million, with A$43.2 million of that landing in the final quarter alone. For context, FY25 produced revenue of A$40.8 million and underlying EBITDA of A$5.1 million.

Why It Matters

Alcidion's Investment case has always hinged on a simple proposition: that a small Australian company could win credibility inside the NHS, one of the most demanding software buyers on earth. Sussex is the clearest evidence yet that the proposition is holding, marking a third UK deployment and, more importantly, a full EPR win rather than a modular sale. That distinction matters because full-suite deals lock customers in for the best part of a decade and pull through years of recurring licence and support revenue. Management has pointed to contracted revenue now extending into the mid-2030s, a visibility profile that provides greater coverage for the near-term Earnings outlook.

Growth Catalysts

Several threads could extend the run. The Kyra acquisition, described as immediately earnings accretive before synergies, hands Alcidion a fresh base of patient-flow customers across Australia, New Zealand and the UK to cross-sell Miya Precision into — a classic land-and-expand opportunity. The Western Health relationship was renewed during the year with a four-year extension plus an optional additional year, underscoring the stickiness of existing accounts. Beyond that, the UK market itself remains a structural opportunity: NHS trusts are under sustained pressure to digitise and to consolidate ageing systems, and each successful full-EPR reference site can support future tender activity. If FY26 guidance of revenue around A$51.6 million and EBITDA above A$5 million is met, Alcidion will have demonstrated it can scale contract wins while maintaining positive earnings.

Risks Investors Should Watch

The outlook is not without risks. The most obvious is that EBITDA guidance of just over A$5 million is barely ahead of FY25's A$5.1 million despite a large step-up in revenue — a signal that the company is reinvesting in delivery and headcount to service its NHS pipeline, and that Operating Leverage may take longer to arrive than the Top Line suggests. Execution risk on Sussex is real too: the deployment is not scheduled to go live until June 2027, and large EPR implementations can face timeline and Margin pressure. Revenue lumpiness is another hazard, given how much of FY26's contract value was front-loaded into a single quarter. Currency exposure to the pound, integration risk on Kyra, and the possibility of NHS budget or procurement disruption also Warrant close attention.

What Happens Next

The 19 August webcast will be judged on more than the audited headline figures, most of which the market can already infer from the quarterly cash-flow reports. Investors will be listening for the shape of the FY27 pipeline, any commentary on further NHS tenders, and early signs that Kyra cross-selling is translating into bookings. Guidance for the year ahead — or the absence of it — will set the tone, as will any update on how the Sussex build is tracking. With much of the FY26 operating performance already disclosed, the result may place greater emphasis on outlook and margin commentary than on the historical numbers themselves.

Conclusion

Alcidion enters its FY26 results with a marquee NHS reference win, a returning profit, record cash generation and revenue visibility stretching into the next decade. Those are the ingredients behind the company's growth narrative, with Miya Precision continuing to underpin its healthcare software strategy. Yet the same progress also raises the bar: with much of FY26 already disclosed and margins guided to remain close to FY25 levels, the burden of proof shifts to management's forward outlook. A clear FY27 pipeline and continued execution could support the next stage of growth; a cautious outlook could limit the response despite a productive FY26. The verdict lands on 19 August.